24 November 2022
Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare to commercialise the Company’s suite of leading cognitive assessment tools in China for both the pharmaceutical and healthcare markets.
12 October 2022
Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd; a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.
17 August 2022
Cambridge Cognition selected by the University of Oxford as a cognitive assessment partner for the ISAP study
Alzheimer's disease validation for NeuroVocalixTM
28 July 2022
We are pleased to announce two agreements in a new therapeutic area for Cambridge Cognition, post-traumatic stress disorder ("PTSD"). Most recently, a research agreement was entered into with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.
18 July 2022
We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.
14 July 2022
It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.
31 May 2022
Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms
Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.